BACKGROUND: High serum alanine aminotransferase (ALT) levels have been associated with increased risk of diabetes and with increased mortality, but associations of variations of ALT in the normal range with outcomes have been less well studied. METHODS: We studied the relationship between ALT, mortality and cardiovascular events in the West of Scotland Coronary Prevention Study (WOSCOPS) and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trials that explicitly excluded subjects with clinically significant liver damage, plus the Leiden 85-plus, a study of survivors to age 85 years. The associations between ALT and morbidity and mortality outcomes were investigated using Cox proportional hazard models adjusting for a comprehensive panel of cardiovascular risk factors. RESULTS: In all three study cohorts, ALT displayed an independent inverse relationship with all-cause mortality so that hazard ratios for fourth versus first quarter of ALT were all below 1.0; HRs 0.64 [95% confidence interval (CI) 0.50-0.81], 0.86 (0.73-1.01), 0.66 (0.50-0.87); WOSCOPS, PROSPER, Leiden 85-plus, respectively. In WOSCOPS and PROSPER, ALT was also inversely associated with risk of fatal plus non-fatal cardiovascular events, including coronary heart disease (CHD) events and stroke. CONCLUSIONS: In three independent populations, ALT in the normal range displayed an inverse relationship with total mortality, cardiovascular events and non-cardiovascular events in middle-to-older aged subjects without evidence of clinically significant liver damage, independent of traditional cardiovascular and other risk factors. These findings indicate that the relationship between ALT and clinical outcomes is more complex than generally appreciated.
BACKGROUND: High serum alanine aminotransferase (ALT) levels have been associated with increased risk of diabetes and with increased mortality, but associations of variations of ALT in the normal range with outcomes have been less well studied. METHODS: We studied the relationship between ALT, mortality and cardiovascular events in the West of Scotland Coronary Prevention Study (WOSCOPS) and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trials that explicitly excluded subjects with clinically significant liver damage, plus the Leiden 85-plus, a study of survivors to age 85 years. The associations between ALT and morbidity and mortality outcomes were investigated using Cox proportional hazard models adjusting for a comprehensive panel of cardiovascular risk factors. RESULTS: In all three study cohorts, ALT displayed an independent inverse relationship with all-cause mortality so that hazard ratios for fourth versus first quarter of ALT were all below 1.0; HRs 0.64 [95% confidence interval (CI) 0.50-0.81], 0.86 (0.73-1.01), 0.66 (0.50-0.87); WOSCOPS, PROSPER, Leiden 85-plus, respectively. In WOSCOPS and PROSPER, ALT was also inversely associated with risk of fatal plus non-fatal cardiovascular events, including coronary heart disease (CHD) events and stroke. CONCLUSIONS: In three independent populations, ALT in the normal range displayed an inverse relationship with total mortality, cardiovascular events and non-cardiovascular events in middle-to-older aged subjects without evidence of clinically significant liver damage, independent of traditional cardiovascular and other risk factors. These findings indicate that the relationship between ALT and clinical outcomes is more complex than generally appreciated.
Authors: Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi; Antonio Picardi Journal: J Gerontol A Biol Sci Med Sci Date: 2018-06-14 Impact factor: 6.053
Authors: Mariana Lazo; Jonathan Rubin; Jeanne M Clark; Josef Coresh; Andrea L C Schneider; Chiadi Ndumele; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin Journal: J Hepatol Date: 2014-11-27 Impact factor: 25.083
Authors: Wai Hoong Chang; Stefanie H Mueller; Sheng-Chia Chung; Graham R Foster; Alvina G Lai Journal: J Transl Med Date: 2022-01-03 Impact factor: 5.531
Authors: Linsay McCallum; Jeemon Panniyammakal; Claire E Hastie; Jonathan Hewitt; Rajan Patel; Gregory C Jones; Scott Muir; Matthew Walters; Naveed Sattar; Anna F Dominiczak; Sandosh Padmanabhan Journal: Hypertension Date: 2015-05-04 Impact factor: 10.190
Authors: Anne H van Houwelingen; Wendy P J den Elzen; Simon P Mooijaart; Margot Heijmans; Jeanet W Blom; Anton J M de Craen; Jacobijn Gussekloo Journal: PLoS One Date: 2013-03-04 Impact factor: 3.240
Authors: Ming-Ming He; Zhe Fang; Dong Hang; Feng Wang; Georgios Polychronidis; Liang Wang; Chun-Han Lo; Kai Wang; Rong Zhong; Markus D Knudsen; Scott G Smith; Rui-Hua Xu; Mingyang Song Journal: Int J Cancer Date: 2020-11-02 Impact factor: 7.316